Sponsor or institution

Clinical trials and research at Dizal Pharmaceuticals

• 15Clinical trials
• 1New in 30 days
• 5Countries

Newest trials

All recruiting trials (15)

• Proton pump inhibitor effect on a cancer-related drug in healthy people

  This early-phase study tests whether rabeprazole changes how the drug DZD8586 behaves in the body, in healthy adult volunteers.

  Recruiting Phase 1 Dizal Pharmaceuticals · Beijing, Beijing Municipality · NCT07888569

• GW5282 with golidocitinib versus CHOP for peripheral T‑cell lymphoma

  This will test whether combining GW5282 with golidocitinib helps adults with peripheral T‑cell lymphoma more than standard CHOP chemotherapy.

  Recruiting Phase 1/2 Dizal Pharmaceuticals · Chongqing, Chongqing Municipality and 11 other locations · NCT07496229

• GW5282 treatment for adults with advanced solid tumors

  This trial will test GW5282 to see if it's safe, how it's processed in the body, and whether it helps adults with locally advanced or metastatic solid tumors who have finished standard treatments.

  Recruiting at 3 sites Phase 1/2 Dizal Pharmaceuticals · Beijing, Beijing Municipality and 2 other locations · NCT07328217

• DZD8586 treatment for adults with primary immune thrombocytopenia (ITP)

  This trial will try different doses of the experimental drug DZD8586 to see if it raises platelet counts and is safe in adults with primary ITP who did not respond to at least one standard treatment.

  Recruiting Phase 2 Dizal Pharmaceuticals · Jinan, Shandong · NCT07294365

• Golidocitinib versus physician-selected therapy for relapsed/refractory peripheral T‑cell lymphoma (Phase 3 JACKPOT19)

  This Phase 3 test compares golidocitinib with treatments chosen by a doctor to see if it better controls disease in adults with relapsed or refractory peripheral T‑cell lymphoma.

  Recruiting at 50 sites Phase 3 Dizal Pharmaceuticals · Hefei, Anhui and 50 other locations · NCT07234162

• Sunvozertinib as follow-up treatment after surgery for early-stage NSCLC with EGFR exon 20 insertion or PACC mutations

  This trial tests whether taking sunvozertinib after complete surgery can lower the chance of cancer coming back in adults with stage IB–IIIA non-small cell lung cancer whose tumors have EGFR exon 20 insertion or PACC mutations.

  Recruiting at 4 sites Phase 3 Dizal Pharmaceuticals · Beijing and 48 other locations · NCT07182682

• DZD8586 plus venetoclax for CLL/SLL

  This will try DZD8586 together with venetoclax in adults with newly diagnosed or treatment‑naïve CLL/SLL who need therapy.

  Recruiting at 14 sites Phase 2 Dizal Pharmaceuticals · Hefei, Anhui and 14 other locations · NCT07154264

• DZD8586 compared with doctor’s choice treatments for relapsed/refractory CLL/SLL

  This trial will test whether the oral drug DZD8586 works better than commonly chosen treatments for adults with relapsed or refractory CLL/SLL.

  Recruiting at 2 sites Phase 3 Dizal Pharmaceuticals · Nanjing, Jiangsu and 1 other locations · NCT07139873

• DZD6008 plus sunvozertinib for advanced EGFR‑mutant non‑small cell lung cancer

  This will test whether combining oral EGFR inhibitor DZD6008 with sunvozertinib is safe and helps shrink tumors in adults with advanced EGFR‑mutant non‑small cell lung cancer.

  Recruiting at 9 sites Phase 1/2 Dizal Pharmaceuticals · Beijing, Beijing Municipality and 13 other locations · NCT07079475

• DZD6008 plus chemotherapy for advanced EGFR‑mutant non‑small cell lung cancer

  This tests whether DZD6008 combined with chemotherapy is safe and can shrink tumors in adults with advanced EGFR‑mutant non‑small cell lung cancer who have progressed after EGFR TKIs.

  Recruiting Phase 1/2 Dizal Pharmaceuticals · Shanghai, Shanghai Municipality · NCT07070440

• DZD8586 combined with immunochemotherapy for diffuse large B‑cell lymphoma

  This trial tests whether adding DZD8586 to standard immunochemotherapy helps people with diffuse large B‑cell lymphoma respond better and what side effects occur.

  Recruiting at 12 sites Phase 1/2 Dizal Pharmaceuticals · Beijing and 12 other locations · NCT07059650

• Oral EGFR inhibitor DZD6008 (sunvozertinib) for advanced EGFR‑mutant non‑small cell lung cancer

  This trial tests an oral EGFR inhibitor called DZD6008 (sunvozertinib) to see if it is safe and can shrink tumors in adults with advanced EGFR‑mutant non‑small cell lung cancer, including patients who have progressed after prior EGFR TKIs or who are treatment‑naïve.

  Recruiting at 2 sites Phase 1 Dizal Pharmaceuticals · New York, New York and 4 other locations · NCT06905197

• Evaluating DZD6008 for advanced lung cancer with EGFR mutations

  This study is testing a new oral medication called DZD6008 to see if it can safely help people with advanced lung cancer who have specific EGFR mutations.

  Recruiting Phase 1 Dizal Pharmaceuticals · Beijing, Beijing Municipality · NCT06813365

• Treatment for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

  This study is testing a new drug called DZD8586 to see if it can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma whose cancer has come back or isn’t responding to other treatments.

  Recruiting at 16 sites Phase 2 Dizal Pharmaceuticals · Hefei, Anhui and 16 other locations · NCT06539182

• Combination therapy for advanced lung cancer with specific mutations

  This study tests a new combination treatment for advanced lung cancer patients with specific mutations to see if it helps them better than current options.

  Recruiting Phase 2 Dizal Pharmaceuticals · Shanghai, Shanghai Municipality · NCT06276283

Quick answers

How many clinical trials run by Dizal Pharmaceuticals are recruiting right now?

15, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 5 countries. The most sites are in China (14 trials), Taiwan (1 trial), Thailand (1 trial), Australia (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 5, Phase 2: 4, Phase 3: 3, Phase 1: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →